A real-world disproportionality analysis of colchicine: data mining of the public version of FDA Adverse Event Reporting System

被引：0

作者：

Xu, Ye ^{[1
]}

Dai, Zhilie ^{[1
]}

Tian, Guowei ^{[1
]}

He, Liqun ^{[1
]}

机构：

[1] Intervent Cardiol Ctr, Dept Cardiol, 215 Zhongshan Ave, Wuhan 430022, Hubei, Peoples R China

来源：

EXPERT OPINION ON DRUG SAFETY | 2024年

关键词：

Colchicine; data mining; FAERS; pharmacovigilance; adverse drug reaction; RANDOMIZED-TRIAL; DOUBLE-BLIND; PERICARDITIS; PREVENTION; MULTICENTER; OVERDOSE;

D O I：

10.1080/14740338.2024.2442053

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

BackgroundColchicine is widely used for gout and familial Mediterranean fever (FMF) and has cardiovascular benefits. However, it is linked to various adverse drug reactions (ADRs). This study aimed to analyze colchicine-related ADRs using FAERS data for safer clinical use.Research design and methodsFAERS data from April 2005 to March 2024 were analyzed using ROR, PRR, BCPNN, and EBGM algorithms. ADRs were categorized by System Organ Classes (SOCs) and Preferred Terms (PTs).ResultsA total of 2,435 colchicine-related ADRs were identified. The most significant SOCs were Injury, poisoning, and procedural complications (n = 1,197, EBGM05 = 6.59) and Gastrointestinal disorders (n = 817, EBGM05 = 7.34). At the PT level, notable ADRs included Neuromyopathy (n = 27, EBGM05 = 153.12), Toxic cardiomyopathy (n = 8, EBGM05 = 138.58), and Spur cell anemia (n = 3, EBGM05 = 88.06). New signals at the PT level, including Necrotizing myositis (n = 6, EBGM05 = 31.22) and Septic arthritis staphylococcal (n = 3, EBGM05 = 28.94), were detected.ConclusionsContinuous monitoring is essential to detect established and emerging ADRs. These findings enhance understanding of colchicine's safety profile, with further research needed to validate these signals.

引用

页数：8

共 50 条

[41] A real-world pharmacovigilance study of FDA adverse event reporting system events for daratumumab [J].

Yun, Xiaolin ;

Zhou, Yingying ;

Wu, Danna ;

Liu, Yuanbo ;

Wu, Qiongshi .

EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) :581-591

[42] A real-world pharmacovigilance study of FDA adverse event reporting system events for atogepant [J].

Wen, Heli ;

Ding, Yitian ;

Chen, Feichi .

EXPERT OPINION ON DRUG SAFETY, 2025, 24 (06) :745-752

[43] Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone [J].

Huang, Youqi ;

Gao, Hongjin ;

Lin, Yuze ;

Chen, Xiaowen ;

Chen, Mingyu ;

Chen, Min .

EXPERT OPINION ON DRUG SAFETY, 2024,

[44] Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system [J].

Gui, Xiujuan ;

Zhao, Jianli ;

Ding, Linxiaoxiao ;

Chai, Jie ;

Lai, Hongna ;

Cai, Yangyang ;

Luo, Simin ;

Zeng, Yinduo ;

Wu, Wenjing ;

Chen, Haizhu ;

Yao, Herui ;

Wang, Ying .

FRONTIERS IN ONCOLOGY, 2023, 13

[45] Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system [J].

Zhu, Zhou ;

Liu, Mingjuan ;

Zhang, Hanlin ;

Zheng, Heyi ;

Li, Jun .

EXPERT OPINION ON DRUG SAFETY, 2025, 24 (05) :599-606

[46] Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system [J].

Jing Huang ;

Yuntao Jia ;

Shusen Sun ;

Long Meng .

BMC Pharmacology and Toxicology, 21

[47] Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system [J].

Huang, Jing ;

Jia, Yuntao ;

Sun, Shusen ;

Meng, Long .

BMC PHARMACOLOGY & TOXICOLOGY, 2020, 21 (01)

[48] A disproportionality analysis of FDA adverse event reporting system events for misoprostol [J].

Yang, Li ;

Xu, Wenting .

SCIENTIFIC REPORTS, 2025, 15 (01)

[49] The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system [J].

Zhou, Yue ;

Wu, Yutong ;

Zhao, Xiao ;

Xu, Lingxu ;

Sun, Mingguang ;

Meng, Zhaoyou .

FRONTIERS IN IMMUNOLOGY, 2025, 16

[50] The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system [J].

Wu, Yutong ;

Zhou, Yue ;

Xia, Shiyue ;

Meng, Zhaoyou .

FRONTIERS IN IMMUNOLOGY, 2025, 16

← 1 2 3 4 5 →